Alumis falls after trial setback for lead drug (ALMS:NASDAQ)
· seekingalpha.com
Alumis (ALMS) stock slides as a mid-stage trial for the company's lead drug in systemic lupus erythematosus fails. Read more here.
Alumis (ALMS) traded sharply lower on Tuesday after the company’s lead asset, envudeucitinib, failed in a mid-stage trial for patients with systemic lupus ery...